1Lok AS, Lai CL, Leung N, et al. 5-year follow-up of 998 chronic hepatitis B patients to determine long-term safety of lamivudine and clinical consequences of lamivudine resistant mutations. Hepatology, 2003,38(4 suppl 1)∶708A.
2David M, Hie-WonLH, Maria B, et al. Significant clinical improvement following the addition of adefovir dipivoxil to lamivudine in decompensated patients with YMDD variant HBV and a reduced response to lamivudine. Hepatology, 2002,36∶625A.
3Pemillo R, Schiff E,Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 2000,32∶129-134.
